Chronic hepatitis B Virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). While multiple treatment modalities are available, liver transplantation remains the sole curative treatment for adv...Chronic hepatitis B Virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). While multiple treatment modalities are available, liver transplantation remains the sole curative treatment for advanced stages of HCC, and hence new treatment approaches are required to fulfill this unmet need of curative HCC therapy. Our first-in-man proof-of-concept adoptive T-cell immunotherapy against HBV related hepatocellular carcinoma metastases has shown promising results. Here, we review the development of T-cell immunotherapy targeting HBV antigens for the treatment of HBV-HCC and discuss the practical considerations for the safe and effective use in clinics.展开更多
Hepatocellular carcinoma(HCC)is a deadly malignancy which typically occurs in the context of chronic liver inflammation.Chronic hepatitis B virus(HBV)infection is considered a major global cause of HCC development.At ...Hepatocellular carcinoma(HCC)is a deadly malignancy which typically occurs in the context of chronic liver inflammation.Chronic hepatitis B virus(HBV)infection is considered a major global cause of HCC development.At the moment,liver transplantation is the only curative modality for HBV-associated HCC.However,some patients develop HBV-HCC recurrence after liver transplantation,leaving them with very limited therapeutic options.Adoptive cell therapy with HBV-specific T cell receptor(TCR)that redirects T cells against HCC relapses has shown promising results in such HBV-HCC patients.In this mini-review,we discuss the application of this personalized T cell therapy,and highlight mRNA electroporation as an efficient tool for engineering safe and efficient TCR-redirected T cells for the treatment of liver transplant patients with HBV-HCC metastasis.展开更多
文摘Chronic hepatitis B Virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). While multiple treatment modalities are available, liver transplantation remains the sole curative treatment for advanced stages of HCC, and hence new treatment approaches are required to fulfill this unmet need of curative HCC therapy. Our first-in-man proof-of-concept adoptive T-cell immunotherapy against HBV related hepatocellular carcinoma metastases has shown promising results. Here, we review the development of T-cell immunotherapy targeting HBV antigens for the treatment of HBV-HCC and discuss the practical considerations for the safe and effective use in clinics.
基金This work was supported by a Singapore Translational Research(STaR)investigator award[MOH-000019(MOH_STaR17nov-001)]a National Research Foundation(Singapore)award(NRF-CRP17-2017-06).
文摘Hepatocellular carcinoma(HCC)is a deadly malignancy which typically occurs in the context of chronic liver inflammation.Chronic hepatitis B virus(HBV)infection is considered a major global cause of HCC development.At the moment,liver transplantation is the only curative modality for HBV-associated HCC.However,some patients develop HBV-HCC recurrence after liver transplantation,leaving them with very limited therapeutic options.Adoptive cell therapy with HBV-specific T cell receptor(TCR)that redirects T cells against HCC relapses has shown promising results in such HBV-HCC patients.In this mini-review,we discuss the application of this personalized T cell therapy,and highlight mRNA electroporation as an efficient tool for engineering safe and efficient TCR-redirected T cells for the treatment of liver transplant patients with HBV-HCC metastasis.
